Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Patria (AVX/COVID-12) Vaccine
NCT04871737Phase 1Completed
- Sponsor
- Avi-Mex
- Start
- May 2021
- Primary completion
- Aug 2022
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of Patria in coronavirus disease 2019 (COVID-19) (10 arms), sponsored by Avi-Mex. Primary endpoints: Incidence of Adverse Events at Day 365, Pregnancy test at Day 14 and 2 more. Started May 2021; status: completed.
02
Drugs
Patria
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04871737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04871737.